Cargando…

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

BACKGROUND: Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability of remission by this approach in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Hejin, Wang, Zhenguang, Wang, Yao, Liu, Yang, Dai, Hanren, Tong, Chuan, Guo, Yelei, Guo, Bo, Ti, Dongdong, Han, Xiao, Yang, Qingming, Wu, Zhiqiang, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558895/ https://www.ncbi.nlm.nih.gov/pubmed/31182121 http://dx.doi.org/10.1186/s13045-019-0741-6

Ejemplares similares

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
por: Zhang, Yajing, et al.
Publicado: (2021)

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
por: Guo, Yelei, et al.
Publicado: (2022)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
por: Dai, Hai-ping, et al.
Publicado: (2022)

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation
por: Kalin, Burak, et al.
Publicado: (2020)

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
por: Wang, Yao, et al.
Publicado: (2018)

CD4(+)FOXP3(+) Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2019)

Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL
por: Yu, Changlin, et al.
Publicado: (2020)

Overview of the progress on haploidentical hematopoietic transplantation
por: Farhadfar, Nosha, et al.
Publicado: (2016)

Review of Haploidentical Hematopoietic Cell Transplantation
por: Khan, Mehreen A., et al.
Publicado: (2018)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
por: Zhao, Houli, et al.
Publicado: (2020)

Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Haploidentical Hematopoietic Stem-Cell Transplantation in Adults
por: Alshemmari, Salem, et al.
Publicado: (2011)

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
por: Xu, Xueer, et al.
Publicado: (2023)

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
por: Feng, Kaichao, et al.
Publicado: (2017)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report
por: Zhang, Cheng, et al.
Publicado: (2019)

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study
por: Chang, Ying-Jun, et al.
Publicado: (2020)

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
por: Yao, Sun, et al.
Publicado: (2019)

Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation
por: Baumeister, Susanne H. C., et al.
Publicado: (2020)

Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2020)

Advances in haploidentical stem cell transplantation
por: Bayraktar, Ulas Darda, et al.
Publicado: (2011)

The Evolution of T Cell Depleted Haploidentical Transplantation
por: Aversa, Franco, et al.
Publicado: (2019)

Haploidentical γδ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma
por: Bold, Anna, et al.
Publicado: (2023)

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
por: Dai, Hanren, et al.
Publicado: (2020)

Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study
por: Ukrainskaya, Valeria, et al.
Publicado: (2022)

Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy
por: Wang, Kai, et al.
Publicado: (2020)

Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies
por: Fabricius, William A., et al.
Publicado: (2016)

Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation
por: Aversa, Franco, et al.
Publicado: (2016)

T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy
por: Takahashi, Takuto, et al.
Publicado: (2022)

Removal of CD276(+) cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD
por: Hashimoto, Hisayoshi, et al.
Publicado: (2021)

Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment
por: Hu, Guanhua, et al.
Publicado: (2022)

T cell depleted haploidentical transplantation: positive selection
por: Aversa, Franco
Publicado: (2011)

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
por: Reagan, John L., et al.
Publicado: (2012)

Strategies in Haploidentical Stem Cell Transplantation in Adults
por: Bayraktar, Ulaş D., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_torto83cr8lttlhauu2oek0esd